PellePharm’s founders are pioneers in the field of hedgehog signaling with the validated preclinical mouse models. Two of our founders, Drs. Epstein and Tang, are experts in conducting clinical trials with hedgehog inhibitors in Gorlin syndrome and sporadic basal cell carcinomas. Hear them introduce themselves, their research, and PellePharm’s topical patidegib drug candidate in the video below.